{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/erectile-dysfunction/prescribing-information/phosphodiesterase-5-pde-5-inhibitors/","result":{"pageContext":{"chapter":{"id":"0d5ad6d5-d065-5eb5-99c8-b654497d8d19","slug":"phosphodiesterase-5-pde-5-inhibitors","fullItemName":"Phosphodiesterase-5 (PDE-5) inhibitors","depth":2,"htmlHeader":"<!-- begin field d067773f-c5fa-41d3-baa6-88d08b8895e5 --><h2>Phosphodiesterase-5 (PDE-5) inhibitors</h2><!-- end field d067773f-c5fa-41d3-baa6-88d08b8895e5 -->","summary":"","htmlStringContent":"<!-- begin item 2a8fe492-a9ec-48e5-8e40-015d1adc723c --><!-- end item 2a8fe492-a9ec-48e5-8e40-015d1adc723c -->","topic":{"id":"5bdc98b8-cec1-551c-a1ea-d279c1d4a789","topicId":"a255a0a6-1216-4961-a8d2-0841d9ddf8fe","topicName":"Erectile dysfunction","slug":"erectile-dysfunction","lastRevised":"Last revised in July 2020","chapters":[{"id":"60de3c56-e8f8-5ed1-af6c-079fbfc5297a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1390eb84-15de-5511-a888-7aa10c5f380e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6f0e3524-4bd9-524b-b0c7-5df8463a2632","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6f8d7396-341b-5cdb-9ab7-11d371aecf1b","slug":"changes","fullItemName":"Changes"},{"id":"7273623f-46a6-55a9-b20f-3174d857bb0b","slug":"update","fullItemName":"Update"}]},{"id":"954f3dd9-902d-5807-89cb-b68e9a352975","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4dbc024b-ad9c-5c73-975f-44d47f56c8db","slug":"goals","fullItemName":"Goals"},{"id":"3c8ab157-63cf-5e79-95c8-8d533751d80b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c87478c5-0e05-5e5e-aff4-92c6bd965c7e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7aad46cb-3cd1-586a-9eb7-5b41fb304896","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"792aba04-631e-555e-8bf8-2c58ec675d8d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19da5bcc-2817-5766-9335-d7974d14f3c4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9a1a9a32-e4af-5cb5-83a9-c382b1ee5d40","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ecd0b9da-d509-587d-9c32-4e2828d198af","slug":"definition","fullItemName":"Definition"},{"id":"a0eac8e3-a0a4-5026-870e-24f5a5597b63","slug":"causes","fullItemName":"Causes"},{"id":"1e4fb7fb-80f2-58a9-9f0a-cd2a06bd58f5","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8f1a78ac-cb2e-5627-aaf2-9eddf7d19863","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fd7eccbd-c104-54ec-aa7e-7b5d8c806ded","slug":"prognosis","fullItemName":"Prognosis"},{"id":"3dbe567c-f646-542c-a649-49c5e0a2e1d8","slug":"complications","fullItemName":"Complications"}]},{"id":"a7b9bdc4-1390-5184-aa4d-a331be735168","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"bdb32096-c2e0-55ac-b935-a61204406095","slug":"assessment","fullItemName":"Assessment"}]},{"id":"7b089806-f4ac-58ac-a788-629e509b4868","fullItemName":"Management","slug":"management","subChapters":[{"id":"09f9cf76-1bbb-5d37-8bf8-9ed3fd4a9b64","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"92e38517-29a0-5e5f-8e17-2959aa09e71a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0d5ad6d5-d065-5eb5-99c8-b654497d8d19","slug":"phosphodiesterase-5-pde-5-inhibitors","fullItemName":"Phosphodiesterase-5 (PDE-5) inhibitors"}]},{"id":"f021401a-d917-5e2c-b234-816a1108de92","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c0f733e9-9f61-5807-8fce-90a6aba44893","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ab85ccb2-6023-521d-b0ed-2cf9647aff63","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"536d66ad-375a-52d4-a2ee-1dfc1ec8a13e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d1ea3b0d-cce2-5191-82e1-3149d32c0296","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c69a15f7-87a5-5513-b5d1-b21a85dd1561","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1d54146b-d6e9-54f2-885a-74200666af7c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"04d092eb-cbf9-5bce-9d0d-65e9e5d6ba1b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"92e38517-29a0-5e5f-8e17-2959aa09e71a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"db95bdab-acab-589b-9f1a-c25559da91ee","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 5143b35c-b04a-4bb5-92f9-1a88ba5d5b99 --><h3>What are the contraindications and cautions?</h3><!-- end field 5143b35c-b04a-4bb5-92f9-1a88ba5d5b99 -->","summary":"","htmlStringContent":"<!-- begin item 524a9db5-a8c4-4d0e-803e-ebacb9cc2a6a --><!-- begin field 8ffdfe3e-ae66-4e88-a094-986d35109e41 --><h4>Contraindications</h4><ul><li><strong>Do not prescribe a phosphodiesterase-5 (PDE-5)inhibitor to men:</strong><ul><li>Receiving certain drugs, including nitrates and guanylate cyclase stimulators (such as riociguat). See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/erectile-dysfunction/prescribing-information/phosphodiesterase-5-pde-5-inhibitors/#drug-interactions\">Drug interactions</a> for more information.</li><li>In whom vasodilation or sexual activity is not recommended. This includes men with severe/unstable heart disease. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/erectile-dysfunction/diagnosis/assessment/#cardiac-risk-stratification\">Cardiac risk stratification</a> for further information.</li><li>Who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure.</li><li>With hypotension (systolic blood pressure below 90/50 mmHg).</li><li>With unstable angina or angina occurring during sexual intercourse. </li></ul></li><li><strong>In addition:</strong><ul><li><strong>Sildenafil</strong> is contraindicated in men with recent history of stroke or myocardial infarction, severe hepatic impairment, and hereditary degenerative retinal disorders (such as retinitis pigmentosa).</li><li><strong>Tadalafil</strong> is contraindicated in men with history of stroke (within the last 6 months) or myocardial infarction (within the last 90 days), New York Heart Association (NYHA) class II or greater heart failure (within the last 6 months), uncontrolled arrhythmias, or uncontrolled hypertension.</li><li><strong>Vardenafil</strong> is contraindicated in men with history of stroke or myocardial infarction (within the last 6 months), severe hepatic impairment, end stage renal disease requiring dialysis, and known hereditary degenerative retinal disorders (such as retinitis pigmentosa).</li><li><strong>Avanafil </strong>is contraindicated in men with a history of stroke, myocardial infarction, life-threatening arrhythmia (within the last 6 months), hypertension (blood pressure greater than 170/100 mmHg), NYHA class II or greater heart failure, severe hepatic impairment (Child-Pugh C), severe renal impairment (creatinine clearance less than 30 mL/minute), and known hereditary degenerative retinal disorders.</li></ul></li></ul><h4>Cautions</h4><ul><li><strong>Prescribe PDE-5 inhibitors with caution to men with:</strong><ul><li>Cardiovascular disease. Consider the potential cardiac risk of sexual activity in men with pre-existing cardiovascular disease before prescribing a PDE-5 inhibitor. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/erectile-dysfunction/diagnosis/assessment/#cardiac-risk-stratification\">Cardiac risk stratification</a> for further information. </li><li>Left ventricular outflow obstruction (for example aortic stenosis and idiopathic hypertrophic subaortic stenosis).</li><li>Anatomical deformation of the penis (for example angulation, cavernosal fibrosis, or Peyronie's disease).</li><li>A predisposition to priapism (for example in sickle-cell disease, multiple myeloma, or leukaemia).</li></ul></li><li><strong>In addition:</strong><ul><li><strong>Prescribe vardenafil</strong> with caution to elderly men and men with active peptic ulceration, bleeding disorders, or susceptibility to prolongation of QT interval.</li><li><strong>Prescribe sildenafil and avanafil </strong>with caution to men with active peptic ulceration or bleeding disorders.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BNF 74, 2017</a>]</p><!-- end field 8ffdfe3e-ae66-4e88-a094-986d35109e41 --><!-- end item 524a9db5-a8c4-4d0e-803e-ebacb9cc2a6a -->","subChapters":[]},{"id":"2daa5f68-5ed4-5dc8-96e0-6dc9cb2a842b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a282a085-3f04-41e0-9990-9ed3ff839ff6 --><h3>Adverse effects</h3><!-- end field a282a085-3f04-41e0-9990-9ed3ff839ff6 -->","summary":"","htmlStringContent":"<!-- begin item a9590b70-f82b-49c2-8ea8-91cf647f205c --><!-- begin field 7c720283-3d56-43c0-bc96-fdd43c08bb10 --><ul><li><strong>Common or very common adverse effects of </strong><strong>phosphodiesterase-5 (PDE-5) inhibitors</strong> <strong>include </strong>back pain, dyspepsia, flushing, migraine, myalgia, nasal congestion, dizziness, nausea, and vomiting.</li><li><strong>Uncommon but serious adverse effects of PDE-5 inhibitors include:</strong><ul><li>Visual disturbances, including non-arteritic anterior ischaemic optic neuropathy (NAION). Stop the PDE-5 inhibitor if sudden visual impairment occurs.</li><li>Sudden hearing loss. Advise the man to stop taking tadalafil and seek prompt medical attention if there is a sudden decrease or loss of hearing.</li><li>Priapism (persistent erection). Warn the man to seek advice if he has an erection lasting longer than 4 hours.</li></ul></li><li><strong>In addition:</strong><ul><li><strong>For sildenafil:</strong><ul><li><strong>Less common adverse effects include </strong>chest pain, drowsiness, dry mouth, epistaxis, fatigue, hypertension, hypoaesthesia, hypotension, painful red eyes, palpitation, tachycardia, tinnitus, and vertigo. </li><li><strong>Rare adverse effects (and adverse effects with unknown frequency) include </strong>atrial fibrillation, cerebrovascular accident, facial oedema, hypersensitivity reactions, rash, Stevens-Johnson syndrome, syncope, arrhythmia, myocardial infarction (MI), seizures, and unstable angina.</li></ul></li><li><strong>For tadalafil:</strong><ul><li><strong>Less common adverse effects include </strong>hypertension, tachycardia, epistaxis, hypotension, painful red eyes, and palpitation. </li><li><strong>Rare adverse effects (and adverse effects with unknown frequency) include </strong>arrhythmia, MI, retinal vascular occlusion, unstable angina, facial oedema, hypersensitivity reactions, rash, Stevens-Johnson syndrome, syncope, abdominal pain, increased sweating, seizures, serious cardiovascular events, and transient amnesia. </li></ul></li><li><strong>For vardenafil:</strong><ul><li><strong>Less common adverse effects include </strong>drowsiness, dyspnoea, epistaxis, hypertension, hypotension, increased lacrimation, painful red eyes, palpitation, photosensitivity, and tachycardia. </li><li><strong>Rare adverse effects (and adverse effects with unknown frequency) include </strong>anxiety, facial oedema, hypersensitivity reactions, hypertonia, raised intra-ocular pressure, rash, Stevens-Johnson syndrome, syncope, transient amnesia, arrhythmia, MI, retinal vascular occlusion, seizures, serious cardiovascular events, and unstable angina.</li></ul></li><li><strong>For avanafil:</strong><ul><li><strong>Less common adverse effects include </strong>drowsiness, epistaxis, hypertension, hypotension, malaise, painful red eyes, palpitation, and tachycardia. </li><li><strong>Rare adverse effects (and adverse effects with unknown frequency) include </strong>abdominal pain, diarrhoea, dry mouth, facial oedema, gastritis, genital irritation, gout, haematuria, hyperactivity, hyperbilirubinaemia, hypersensitivity reactions, increased serum creatinine, insomnia, muscle spasms, peripheral oedema, pollakiuria, rash, Stevens-Johnson syndrome, syncope, weight gain, arrhythmia, MI, retinal vascular occlusion, seizures, serious cardiovascular events, and unstable angina.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BNF 74, 2017</a>]</p><!-- end field 7c720283-3d56-43c0-bc96-fdd43c08bb10 --><!-- end item a9590b70-f82b-49c2-8ea8-91cf647f205c -->","subChapters":[]},{"id":"088be8a8-fc2c-5b51-81ef-2d7148c68a61","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field fe978017-e0a4-4a96-83a7-8b3008a75dde --><h3>What key drug interactions should I be aware of when prescribing a phosphodiesterase-5 inhibitor?</h3><!-- end field fe978017-e0a4-4a96-83a7-8b3008a75dde -->","summary":"","htmlStringContent":"<!-- begin item 14667352-96e4-448f-9f78-ae9ff55f3ace --><!-- begin field 10f8de77-7462-47e1-9981-adf9c10a2c89 --><p><strong>Key drug interactions with phosphodiesterase-5 (PDE-5) inhibitors include:</strong></p><ul><li><strong>Nitrates </strong>— concurrent use of PDE-5 inhibitors and organic nitrates (such as nitroglycerine, isosorbide mononitrate, or isosorbide dinitrate), nicorandil, or amyl nitrate ('poppers' used for recreation) are absolutely contraindicated.<ul><li>They result in cyclic guanosine monophosphate (cGMP) accumulation and unpredictable falls in blood pressure and symptoms of hypotension. The duration of interaction between organic nitrates and PDE-5 inhibitors depends on the PDE-5 inhibitor and nitrate used.</li><li>If a PDE-5 inhibitor is taken and the man develops chest pain, organic nitrates should not be used for at least 24 hours for sildenafil and possibly vardenafil (half-life 4 hours), 48 hours for tadalafil (due to its longer half-life of 17.5 hours), and at least 12 hours for avanafil (half-life 6–17 hours).</li></ul></li><li><strong>Guanylate cyclase stimulators</strong> — concurrent use is contraindicated.<ul><li>Riociguat has been shown to augment the hypotensive effects of PDE-5 inhibitors. </li></ul></li><li><strong>Alpha-blockers</strong> — concurrent treatment with a PDE-5 inhibitor and an alpha-blocker can increase the risk of postural hypotension as both are vasodilators. <ul><li>PDE-5 inhibitors should not be used by men taking non-selective alpha blockers (such as doxazosin, indoramin, terazosin, or prazosin) unless they have finished alpha-blocker dose titration and are on a stable dose. The manufacturers also state that:<ul><li>Sildenafil should be used with caution in men taking an alpha-blocker (especially doxazosin). Hypotension is more likely to occur within four hours following treatment with an alpha-blocker. A sildenafil starting dose of 25 mg is recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016a</a>].</li><li>Vardenafil should be initiated at the lowest starting dose of 5 mg (if the man has been stabilised on his alpha-blocker treatment). Vardenafil may be given at any time with tamsulosin or alfuzosin but with other alpha-blockers, a time separation of dosing should be considered. In men already taking an optimized dose of vardenafil, alpha-blocker treatment should be initiated at the lowest dose [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017c</a>]. </li><li>Tadalafil is not recommended in men taking doxazosin (due to a significant blood pressure lowering effect). For all other alpha-blockers, tadalafil should be used with caution; treatment should be initiated at minimal dosage and progressively adjusted [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017b</a>]. </li><li>Avanafil should be initiated at the lowest dose of 50 mg. Conversely in men already taking an optimal dose of avanafil, alpha-blocker treatment should be initiated at the lowest dose [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016b</a>].</li></ul></li></ul></li><li><strong>Cytochrome P450 (CYP) 3A4</strong> <strong>and 2C9 inhibitors </strong><strong>may reduce the clearance of PDE-5 inhibitors, as PDE-5 inhibitors are metabolized by this enzyme.</strong><ul><li><strong>Sildenafil </strong><ul><li>With ritonavir — co-administration should be avoided if possible, otherwise a maximum dose of 25 mg of sildenafil within 48 hours must not be exceeded.</li><li>With all other CYP3A4 inhibitors (such as ketoconazole, itraconazole, erythromycin, cimetidine, and grapefruit juice) — a sildenafil starting dose of 25 mg should be considered.</li></ul></li><li><strong>Vardenafil</strong><ul><li>HIV protease inhibitors (such as ritonavir and indinavir; very potent inhibitors of CYP3A4) — co-administration is contraindicated.</li><li>Potent CYP3A4 inhibitors (such as clarithromycin and oral ketoconazole and itraconazole) — co-administration is contraindicated in men older than 75 years and should be avoided in all other men.</li><li>Moderate CYP3A4 inhibitors (such as erythromycin) — vardenafil dose adjustment may be necessary.</li><li>Grapefruit — co-administration should be avoided as concomitant intake of grapefruit or grapefruit juice is expected to increase the plasma concentrations of vardenafil.</li></ul></li><li><strong>Tadalafil </strong><ul><li>Co-administration with CYP3A4 should be avoided if possible, otherwise tadalafil should be initiated at the lowest recommended starting dose.</li></ul></li><li><strong>Avanafil</strong><ul><li>Very potent and potent CYP3A4 inhibitors (such as itraconazole, clarithromycin, saquinavir, and indinavir) — co-administration is contraindicated.</li><li>Moderate CYP3A4 inhibitors (such as erythromycin) — a maximum dose of 100 mg of avanafil within 48 hours must not be exceeded.</li><li>Other CYP3A4 inhibitors — co-administration should be done with caution. </li><li>Grapefruit — the man should be advised to avoid grapefruit juice within 24 hours prior to taking avanafil.</li></ul></li></ul></li><li><strong>CYP3A4 inducers (such as rifampin, phenobarbital, phenytoin, and carbamazepine) may enhance the clearance of PDE-5 inhibitors.</strong><ul><li>Co-administration should be avoided if possible, otherwise, higher doses of the PDE-5 inhibitor may be required.</li></ul></li><li><strong>For a complete list of possible drug interactions of </strong><strong>PDE-5 inhibitors, see the <a href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\" data-hyperlink-id=\"2f100dbc-92fe-4358-b6b1-a9920125168e\">electronic Medicines Compendium</a> (eMC) or the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"e0c966b5-f7fc-44a4-a153-a992012516b7\">British National Formulary</a> (BNF).</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017c</a>] </p><!-- end field 10f8de77-7462-47e1-9981-adf9c10a2c89 --><!-- end item 14667352-96e4-448f-9f78-ae9ff55f3ace -->","subChapters":[]},{"id":"30827057-340d-5a40-84f0-2eba4eacc153","slug":"dosing-regimen","fullItemName":"Dosing regimen","depth":3,"htmlHeader":"<!-- begin field 7debfd2b-5315-40df-a870-70775010a6a3 --><h3>Dosing regimen</h3><!-- end field 7debfd2b-5315-40df-a870-70775010a6a3 -->","summary":"","htmlStringContent":"<!-- begin item 1cd5ae39-4970-4458-81dc-53d38d17ffae --><!-- begin field 938c34d1-fb2f-4dee-bc7e-5a443db45e92 --><ul><li><strong>For most men, as-required treatment with a phosphodiesterase-5 (PDE-5) inhibitor is suitable. </strong>The frequency of treatment will need to be considered on an individual basis. <ul><li>The Health Service Circular <em>Treatment for impotence</em> recommends<em> </em>one treatment a week on the NHS, based on research evidence that the frequency of sexual intercourse in the 40–60 age range is once a week. However, if the GP considers that more than one treatment a week is appropriate, this can be prescribed on the NHS. [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">NHS Executive, 1999</a>].</li></ul></li><li><strong>For sildenafil </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016a</a>]<strong>:</strong><ul><li><strong>The recommended dose is</strong> 50 mg taken as needed approximately one hour before sexual activity (or longer if taken with food). Based on efficacy and tolerability, the dose may be increased to 100 mg or decreased to 25 mg. The maximum recommended dose is 100 mg. The maximum recommended dosing frequency is once per day.</li><li><strong>Renal impairment</strong><ul><li>If the estimated Glomerular Filtration Rate (eGFR) is less than 30 mL/minute/1.73 m<sup>2</sup>, use initial dose of 25 mg. This can be increased to 50 mg, then 100 mg based on efficacy and tolerability.</li><li>No dose adjustment is needed for men with mild to moderate renal impairment.</li></ul></li><li><strong>Hepatic impairment</strong><ul><li>In men with mild to moderate hepatic impairment, consider a starting dose of 25 mg. This can be increased to 50 mg, then 100 mg based on efficacy and tolerability.</li><li>Avoid in men with severe hepatic impairment.</li></ul></li><li><strong>Elderly men </strong><strong>(aged 65 years and older) </strong><ul><li>No dose adjustment is needed.</li></ul></li></ul></li><li><strong>For tadalafil </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017b</a>]<strong>:</strong><ul><li><strong>For most men, the recommended dose is </strong>10 mg (with or without food) taken at least 30 minutes prior to sexual activity. Based on efficacy and tolerability, this can be increased to the maximum dose of 20 mg. The maximum dose frequency is once per day.</li><li><strong>For men who prefer spontaneous (rather than planned) sexual activities or who anticipate frequent sexual activity (more than twice weekly), </strong>tadalafil 2.5 and 5 mg tablets may be considered for daily use (as they are licensed for this indication) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017b</a>].<ul><li>The potential advantage of this regimen is that the man does not have to wait for onset of action before sexual activity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">European Association of Urology, 2017</a>]. However, the available data do not suggest that this regimen gives better results than the standard on demand treatment in the general erectile dysfunction population [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">PrescQIPP, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Bansal et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Peng et al, 2017</a>].</li><li>The appropriateness of continued use of the daily regimen should be based on clinical judgement and patient choice, and reassessed periodically [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">PrescQIPP, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">European Association of Urology, 2017</a>]. </li></ul></li><li><strong>Renal impairment</strong><ul><li>If eGFR is less than 30 mL/minute/1.73m<sup>2</sup>, use a maximum dose of 10 mg. Avoid the regular once-daily dosing regimen.</li><li>No dose adjustment is needed for men with mild to moderate renal impairment.</li></ul></li><li><strong>Hepatic impairment </strong><ul><li>Following a careful individual benefit/risk evaluation, a maximum daily dose of 10 mg once daily should be considered.</li><li>Use with caution in severe impairment and for regular once-daily dosing in erectile dysfunction.</li></ul></li><li><strong>Elderly men </strong><ul><li>No dose adjustment is needed.</li></ul></li></ul></li><li><strong>For vardenafil film coated or orodispersible tablets </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016c</a>]<strong>:</strong><ul><li><strong>The recommended doses are:</strong><ul><li><strong>For vardenafil film coated tablets</strong> — 10 mg (with or without food) taken at least 25–60 minutes before sexual activity (or longer if taken with a high fat meal). Based on efficacy and tolerability, this can be increased to the maximum recommended daily dose of 20 mg or decreased to 5 mg. The maximum recommended dosing frequency is once daily.</li><li><strong>For vardenafil orodispersible tablets</strong> — 10 mg (with or without food) taken at least 25–60 minutes before sexual activity (not affected by fatty meals). The maximum recommended dose is 10 mg a day. The maximum recommended dosing frequency is once daily.</li></ul></li><li><strong>Renal impairment </strong><ul><li><strong>For vardenafil film coated tablets</strong> — no dose adjustment is needed for men with mild to moderate renal impairment. In men with severe renal impairment (eGFR less than 30mL/minute/1.73 m<sup>2</sup>), a starting dose of 5 mg should be considered. This can be increased to 10 mg, then 20 mg based on tolerability and efficacy.  </li><li><strong>For vardenafil orodispersible tablets</strong> — no dose adjustment is needed for men with mild to moderate renal impairment. In men with severe renal impairment (eGFR less than 30 mL/minute/1.73 m<sup>2</sup>), a starting dose of vardenafil 5 mg film-coated tablets should be considered. Based on tolerability and efficacy, the dose may be increased to vardenafil 10 mg and 20 mg film-coated tablets, or vardenafil 10 mg orodispersible tablets. Do not use vardenafil orodispersible tablet in men with end-stage renal failure.</li></ul></li><li><strong>Hepatic impairment</strong><ul><li><strong>For vardenafil film coated tablets</strong> — a starting dose of 5 mg should be considered in men with mild to moderate hepatic impairment. Based on tolerability and efficacy, the dose may subsequently be increased. The maximum dose recommended in men with moderate hepatic impairment is 10 mg.</li><li><strong>For vardenafil orodispersible tablets</strong> — in men with mild hepatic impairment, use a starting dose of vardenafil 5 mg film-coated tablets. Based on tolerability and efficacy, the dose may be increased to vardenafil 10 mg and 20 mg film-coated tablets, or vardenafil 10 mg orodispersible tablets. Do not use vardenafil orodispersible tablet as a starting dose in men with mild hepatic impairment and in men with moderate or severe hepatic impairment.</li></ul></li><li><strong>Elderly men (aged 65 years and older) </strong><ul><li>Dose adjustments are not required. However, an increase to the maximum dose of 20 mg should be carefully considered, depending on the individual tolerability.</li></ul></li></ul></li><li><strong>For avanafil </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016b</a>]<strong>: </strong><ul><li><strong>The recommended dose is </strong>100 mg (with or without food) taken as needed approximately 15–30 minutes before sexual activity (or longer if aken with food). Based on individual efficacy and tolerability, the dose may be increased to a maximum dose of 200 mg or decreased to 50 mg. The maximum recommended dosing frequency is once daily. </li><li><strong>Renal impairment</strong><ul><li>If eGFR is less than 30 mL/minute/1.73 m<sup>2</sup>, do not use avanafil.</li><li>No dose adjustment is needed for men with mild to moderate renal impairment.</li></ul></li><li><strong>Hepatic impairment </strong><ul><li>Do not use avanafil in men with severe hepatic impairment. </li><li>In men with mild to moderate hepatic impairment, use the lowest effective initial dose and adjust according to response.</li></ul></li><li><strong>Elderly men </strong><strong>(aged 65 years and older) </strong><ul><li>No dose adjustment is needed. However, there is limited data for its use in men aged 70 years and older.</li></ul></li></ul></li></ul><!-- end field 938c34d1-fb2f-4dee-bc7e-5a443db45e92 --><!-- end item 1cd5ae39-4970-4458-81dc-53d38d17ffae -->","subChapters":[]},{"id":"b9bae8c2-3e52-5ad2-9fef-97e2cc9b8ff0","slug":"advice-for-patients","fullItemName":"Advice for patients","depth":3,"htmlHeader":"<!-- begin field f951cac7-f6cc-4793-a44c-a82b00dac0e2 --><h3>What should I advise on phosphodiesterase-5 inhibitors?</h3><!-- end field f951cac7-f6cc-4793-a44c-a82b00dac0e2 -->","summary":"","htmlStringContent":"<!-- begin item 2e7c553c-8028-4de5-997b-a82b00dabc87 --><!-- begin field 0114bbfa-72dd-4b44-b286-a82b00dac0e2 --><ul><li><strong>Advise the man that:</strong><ul><li>Lifestyle changes and risk factor modification must precede or accompany treatment with a phosphodiesterase-5 (PDE-5) inhibitor.</li><li>PDE-5 inhibitors are not initiators of erection but require sexual stimulation in order to facilitate erection.</li><li>He should obtain his medication from a reputable pharmacy, as there is a large counterfeit market in PDE-5 inhibitors and the amount of active drug in these medications varies.</li></ul></li><li><strong>Give adequate information on the drug, including</strong> when to take it, time to onset of effect, the duration of action, and the effect of food on the absorption (and hence the onset of effect). See Table 1 for more information.</li></ul><p><strong>Table 1.</strong> Pharmacokinetic comparison of phosphodiesterase-5 (PDE-5) inhibitors.</p><table><thead><tr><th colspan=\"1\"> </th><th colspan=\"1\">Sildenafil</th><th colspan=\"1\">Tadalafil</th><th colspan=\"1\">Vardenafil</th><th colspan=\"1\">Vardenafil orodispersible</th><th colspan=\"1\">Avanafil</th></tr></thead><tbody><tr><td><strong>Time taken before sexual activity</strong></td><td>1 hour</td><td>At least 30 minutes</td><td>25–60 minutes</td><td>25–60 minutes</td><td>15–30 minutes</td></tr><tr><td><strong>Time to reach maximum plasma concentration</strong></td><td>30–120 minutes (median 60 minutes)</td><td>2 hours (median)</td><td>30–120 minutes (median 60 minutes)</td><td>45–90 minutes</td><td>30–45 minutes (median)</td></tr><tr><td><strong>Time to onset of effect</strong></td><td>25 minutes (range 12–37 minutes)</td><td>16 minutes–36 hours</td><td>25 minutes (median range from 15 minutes)</td><td>25 minutes (median range from 15 minutes)</td><td>15–30 minutes</td></tr><tr><td><strong>Duration of action</strong></td><td>4–5 hours</td><td>Up to 36 hours</td><td>4–5 hours</td><td>4–5 hours</td><td>Up to 6 hours</td></tr><tr><td><strong>Effect of food intake</strong></td><td>Rate of absorption reduced by mean 60 minutes when taken with food</td><td>Rate of absorption not affected by food</td><td>Rate of absorption reduced by median 60 minutes when taken with high fat meals</td><td>Rate of absorption reduced by median 60 minutes when taken with high fat meals</td><td>Rate of absorption reduced by mean 75 minutes when taken with high fat meals</td></tr><tr><td colspan=\"6\"><p><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">PrescQIPP, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BNF 74, 2017</a>]</p></td></tr></tbody></table><!-- end field 0114bbfa-72dd-4b44-b286-a82b00dac0e2 --><!-- end item 2e7c553c-8028-4de5-997b-a82b00dabc87 -->","subChapters":[]},{"id":"39b61b56-3eae-522b-bfa5-be794c8b4875","slug":"qualifying-for-an-nhs-prescription","fullItemName":"Qualifying for an NHS prescription","depth":3,"htmlHeader":"<!-- begin field 67444f9d-9ae5-4ec2-bb96-fb587d66020b --><h3>Qualifying for an NHS prescription</h3><!-- end field 67444f9d-9ae5-4ec2-bb96-fb587d66020b -->","summary":"","htmlStringContent":"<!-- begin item e62c9add-b56b-4314-b3a9-f8b66be82edb --><!-- begin field 9c9eb912-4026-41ca-a23c-41200759f587 --><ul><li>Generic sildenafil can be prescribed without restriction on the NHS.</li><li>Viagra<sup>®</sup>, tadalafil (Cialis<sup>®</sup>), vardenafil (Levitra<sup>®</sup>), and avanafil (Spedra<sup>®</sup>) are not prescribable on an NHS prescription except for men who:<ul><li>Have diabetes, multiple sclerosis, Parkinson's disease, poliomyelitis, prostate cancer, severe pelvic injury, single-gene neurological disease (for example Huntington's disease), spina bifida, or spinal cord injury.</li><li>Are receiving renal dialysis for renal failure.</li><li>Have had radical pelvic surgery, prostatectomy (including transurethral resection of the prostrate), or a kidney transplant.</li><li>Were receiving Caverject<sup>®</sup>, Erecnos<sup>®</sup>, MUSE<sup>®</sup>, Uprima<sup>®</sup>, Viagra<sup>®</sup>, Cialis<sup>®</sup>, or Viridal<sup>® </sup>at the expense of the NHS on 14 September 1998.</li></ul></li><li>In addition, specialist centres can prescribe phosphodiesterase-5 (PDE-5) inhibitors on the NHS if the man is 'suffering severe distress as a result of impotence' that causes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">British Society for Sexual Medicine, 2013</a>]:<ul><li>Significant disruption to normal social and occupational activities.</li><li>A marked effect on mood, behaviour, social, and environmental awareness.</li><li>A marked effect on interpersonal relationships.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Prescription Pricing Authority, 2017</a>] </p><!-- end field 9c9eb912-4026-41ca-a23c-41200759f587 --><!-- end item e62c9add-b56b-4314-b3a9-f8b66be82edb -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}